Literature DB >> 27084039

Adaptive immunity in HBV infection.

Antonio Bertoletti1, Carlo Ferrari2.   

Abstract

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately determines HBV infection outcome. In this review, in addition to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral immunity; B lymphocytes; Immunodominance; T cell exhaustion; T lymphocytes

Mesh：

Substances：

Year:  2016        PMID： 27084039     DOI： 10.1016/j.jhep.2016.01.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


  111 in total

1.  Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.

Authors:  Laura Rivino; Nina Le Bert; Upkar S Gill; Kamini Kunasegaran; Yang Cheng; Damien Zm Tan; Etienne Becht; Navjyot K Hansi; Graham R Foster; Tung-Hung Su; Tai-Chung Tseng; Seng Gee Lim; Jia-Horng Kao; Evan W Newell; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-01-08       Impact factor: 14.808

2.  MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes.

Authors:  Benjamin J Burwitz; Patrick K Hashiguchi; Mandana Mansouri; Christine Meyer; Roxanne M Gilbride; Sreya Biswas; Jennie L Womack; Jason S Reed; Helen L Wu; Michael K Axthelm; Scott G Hansen; Louis J Picker; Klaus Früh; Jonah B Sacha
Journal:  J Immunol       Date:  2020-03-11       Impact factor: 5.422

3.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 4.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

5.  Exosomes: multitask cargo carriers modulating innate immunity to viruses.

Authors:  Mario U Mondelli
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

6.  Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.

Authors:  Zhaochun Chen; Giacomo Diaz; Teresa Pollicino; Huaying Zhao; Ronald E Engle; Peter Schuck; Chen-Hsiang Shen; Fausto Zamboni; Zhifeng Long; Juraj Kabat; Davide De Battista; Kevin W Bock; Ian N Moore; Kurt Wollenberg; Cinque Soto; Sugantha Govindarajan; Peter D Kwong; David E Kleiner; Robert H Purcell; Patrizia Farci
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

Review 7.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

8.  Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.

Authors:  Xihua Fu; Haibo Lou; Fang Chen; Xueping Gao; Zhanzhou Lin
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

9.  An OX40/OX40L interaction directs successful immunity to hepatitis B virus.

Authors:  Jean Publicover; Anuj Gaggar; Jillian M Jespersen; Ugur Halac; Audra J Johnson; Amanda Goodsell; Lia Avanesyan; Stephen L Nishimura; Meghan Holdorf; Keith G Mansfield; Joyce Bousquet Judge; Arya Koshti; Michael Croft; Adil E Wakil; Philip Rosenthal; Eric Pai; Stewart Cooper; Jody L Baron
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

10.  PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Authors:  Loghman Salimzadeh; Nina Le Bert; Charles-A Dutertre; Upkar S Gill; Evan W Newell; Christian Frey; Magdeleine Hung; Nikolai Novikov; Simon Fletcher; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-08-07       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.